Micro-X
- Home ›
- AU ›
- Healthcare
Micro-X Limited designs, develops, and manufactures ultra-lightweight carbon nano tube based X-ray products for the healthcare and improvised explosive device imaging security markets in Australia. The last earnings update was 56 days ago. More info.
Add to Portfolio Compare Print
- Micro-X has significant price volatility in the past 3 months.
MX1 Share Price and Events
7 Day Returns
1 Year Returns
MX1 Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Micro-X (MX1) | 1.5% | 20% | 24.5% | -5.7% | -24.1% | - |
| AU Medical Equipment | 0.7% | 3.1% | 0.1% | -1% | 44.1% | 106.9% |
| AU Market | 1.7% | 4% | 8.6% | 5.9% | 21.4% | 7.4% |
1 Year Return vs Industry and Market
- MX1 underperformed the Medical Equipment industry which returned -1% over the past year.
- MX1 underperformed the Market in Australia which returned 5.9% over the past year.
MX1 Value
Is Micro-X undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
In this section, we usually try to help investors determine whether Micro-X is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Micro-X has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
- It is not possible to calculate the future cash flow value for Micro-X. This is due to cash flow or dividend data being unavailable. The share price is A$0.33.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Micro-X's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Micro-X's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in AUD | A$-0.12 |
| ASX:MX1 Share Price ** | ASX (2019-04-24) in AUD | A$0.33 |
| Australia Medical Equipment Industry PE Ratio | Median Figure of 8 Publicly-Listed Medical Equipment Companies | 34.76x |
| Australia Market PE Ratio | Median Figure of 543 Publicly-Listed Companies | 16.28x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Micro-X.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = ASX:MX1 Share Price ÷ EPS (both in AUD) = 0.33 ÷ -0.12 |
-2.66x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Micro-X is loss making, we can't compare its value to the AU Medical Equipment industry average.
- Micro-X is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does
Micro-X's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -2.66x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts |
104.3%per year |
| Oceania Medical Equipment Industry PEG Ratio | Median Figure of 5 Publicly-Listed Medical Equipment Companies | 2.67x |
| Australia Market PEG Ratio | Median Figure of 359 Publicly-Listed Companies | 1.36x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Micro-X, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Micro-X's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in AUD | A$0.00 |
| ASX:MX1 Share Price * | ASX (2019-04-24) in AUD | A$0.33 |
| Australia Medical Equipment Industry PB Ratio | Median Figure of 30 Publicly-Listed Medical Equipment Companies | 2.78x |
| Australia Market PB Ratio | Median Figure of 1,676 Publicly-Listed Companies | 1.66x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = ASX:MX1 Share Price ÷ Book Value per Share (both in AUD) = 0.33 ÷ 0.00 |
-288.71x |
* Primary Listing of Micro-X.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Micro-X has negative assets, we can't compare the value of its assets to the AU Medical Equipment industry average.
Value checks
We assess Micro-X's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check) Micro-X has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
MX1 Future Performance
How is Micro-X expected to perform in the next 1 to 3 years based on estimates from 1 analyst?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Micro-X's earnings growth is expected to exceed the low risk savings rate of 2.3%.
Growth vs Market Checks
- Micro-X's earnings growth is expected to exceed the Australia market average.
- Micro-X's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| ASX:MX1 Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts | 104.3% |
| ASX:MX1 Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts | 114.9% |
| Australia Medical Equipment Industry Earnings Growth Rate | Market Cap Weighted Average | 13.2% |
| Australia Medical Equipment Industry Revenue Growth Rate | Market Cap Weighted Average | 8.4% |
| Australia Market Earnings Growth Rate | Market Cap Weighted Average | 6.8% |
| Australia Market Revenue Growth Rate | Market Cap Weighted Average | 3% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 1 Analyst Estimates (S&P Global) | See Below |
| Date (Data in AUD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2021-06-30 | 68 | 2 | 16 | 1 |
| 2020-06-30 | 17 | -8 | -5 | 1 |
| 2019-06-30 | 4 | -7 | -10 | 1 |
| Date (Data in AUD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 2 | -9 | -18 |
| 2018-09-30 | 2 | -9 | -17 |
| 2018-06-30 | 2 | -8 | -17 |
| 2018-03-31 | 1 | -9 | -14 |
| 2017-12-31 | 1 | -11 | -11 |
| 2017-09-30 | 1 | -11 | -12 |
| 2017-06-30 | 1 | -11 | -13 |
| 2017-03-31 | 1 | -10 | -13 |
| 2016-12-31 | 1 | -9 | -13 |
| 2016-09-30 | 1 | -11 | -12 |
| 2016-06-30 | 1 | -13 | -11 |
| 2016-03-31 | 1 | -10 | -12 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 1 Analyst Estimates (S&P Global) | See Below |
All data from Micro-X Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in AUD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2021-06-30 | 0.09 | 0.09 | 0.09 | 1.00 |
| 2020-06-30 | -0.03 | -0.03 | -0.03 | 1.00 |
| 2019-06-30 | -0.07 | -0.07 | -0.07 | 1.00 |
| Date (Data in AUD Millions) | EPS * |
|---|---|
| 2018-12-31 | -0.12 |
| 2018-09-30 | -0.12 |
| 2018-06-30 | -0.11 |
| 2018-03-31 | -0.10 |
| 2017-12-31 | -0.08 |
| 2017-09-30 | -0.09 |
| 2017-06-30 | -0.10 |
| 2017-03-31 | -0.09 |
| 2016-12-31 | -0.11 |
| 2016-09-30 | -0.10 |
| 2016-06-30 | -0.17 |
| 2016-03-31 | -0.10 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Micro-X will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
Future performance checks
We assess Micro-X's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Micro-X has a total score of 5/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
MX1 Past Performance
How has Micro-X performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Micro-X does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare Micro-X's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Micro-X's 1-year growth to the AU Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
All data from Micro-X Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in AUD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 1.77 | -17.94 | 6.40 | |
| 2018-09-30 | 1.69 | -17.27 | 5.98 | |
| 2018-06-30 | 1.61 | -16.60 | 5.56 | |
| 2018-03-31 | 1.35 | -13.62 | 5.01 | |
| 2017-12-31 | 1.10 | -10.64 | 4.63 | |
| 2017-09-30 | 0.88 | -11.78 | 4.27 | |
| 2017-06-30 | 0.66 | -12.92 | 3.92 | |
| 2017-03-31 | 0.81 | -12.72 | 3.57 | -4.03 |
| 2016-12-31 | 0.97 | -12.51 | 3.23 | -8.06 |
| 2016-09-30 | 0.93 | -11.63 | 2.63 | -4.03 |
| 2016-06-30 | 0.89 | -10.74 | 2.03 | |
| 2016-03-31 | 0.59 | -11.75 | 1.37 | 6.47 |
| 2015-12-31 | 0.28 | -12.76 | 0.70 | 12.94 |
| 2015-09-30 | 0.18 | -11.46 | 0.58 | 10.03 |
| 2015-06-30 | 0.07 | -10.16 | 0.46 | 7.13 |
| 2014-06-30 | -0.39 | 0.14 | 0.30 | |
| 2013-06-30 | 0.08 | 0.00 | 0.29 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Micro-X has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
- It is difficult to establish if Micro-X has efficiently used its assets last year compared to the AU Medical Equipment industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Micro-X improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Micro-X's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Micro-X has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
MX1 Health
How is Micro-X's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Micro-X's finances.
The net worth of a company is the difference between its assets and liabilities.
- Micro-X is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Micro-X's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Micro-X has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Micro-X Company Filings, last reported 3 months ago.
| Date (Data in AUD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | -0.17 | 6.75 | 4.38 |
| 2018-09-30 | -0.17 | 6.75 | 4.38 |
| 2018-06-30 | -0.73 | 9.60 | 4.07 |
| 2018-03-31 | -0.73 | 9.60 | 4.07 |
| 2017-12-31 | 10.53 | 3.00 | 4.10 |
| 2017-09-30 | 10.53 | 3.00 | 4.10 |
| 2017-06-30 | 15.32 | 3.00 | 5.58 |
| 2017-03-31 | 15.32 | 3.00 | 5.58 |
| 2016-12-31 | 11.20 | 2.80 | 5.60 |
| 2016-09-30 | 11.20 | 2.80 | 5.60 |
| 2016-06-30 | 18.23 | 0.00 | 4.17 |
| 2016-03-31 | 18.23 | 0.00 | 4.17 |
| 2015-12-31 | 23.04 | 0.00 | 18.36 |
| 2015-09-30 | 23.04 | 0.00 | 18.36 |
| 2015-06-30 | -10.28 | 15.41 | 2.59 |
| 2014-06-30 | -0.38 | 0.24 | 0.04 |
| 2013-06-30 |
- Micro-X has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
- Irrelevant to check if Micro-X's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Micro-X has less than a year of cash runway based on current free cash flow.
- Micro-X has less than a year of cash runway if free cash flow continues to reduce at historical rates of -4.8% each year.
Financial health checks
We assess Micro-X's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Micro-X has a total score of 2/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
MX1 Dividends
What is Micro-X's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
A$2,000 of
Micro-X
shares you are expected to receive
A$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Micro-X's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Micro-X's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 1 Analyst Estimates (S&P Global) | See Below |
| Oceania Medical Equipment Industry Average Dividend Yield | Market Cap Weighted Average of 5 Stocks | 1.7% |
| Australia Market Average Dividend Yield | Market Cap Weighted Average of 417 Stocks | 4.2% |
| Australia Minimum Threshold Dividend Yield | 10th Percentile | 1.5% |
| Australia Bottom 25% Dividend Yield | 25th Percentile | 2.5% |
| Australia Top 25% Dividend Yield | 75th Percentile | 5.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in A$) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2021-06-30 | 0.00 | 1.00 |
| 2020-06-30 | 0.00 | 1.00 |
| 2019-06-30 | 0.00 | 1.00 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Micro-X has not reported any payouts.
- Unable to verify if Micro-X's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Micro-X's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Micro-X afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Micro-X has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
MX1 Management
CEO
| COMPENSATION | A$321,085 |
| TENURE AS CEO | 4.6 years |
CEO Bio
Mr. Peter Robin Rowland, BSc., MBA, MIET, CEng, FAICD, serves as Managing Director and Executive Director of Micro-X Limited. Mr. Rowland is a laser industry veteran with 25 years' experience in engineering design, development and project management of innovative, high technology military and scientific equipment at BAE Systems. He worked in the engineering design, development and project management of innovative, high-technology military & scientific equipment in his early career in Scotland. In Australia, he ran an engineering design consultancy group, was Director of Business Development at BAE Systems. He served as Managing Director and Vice President of BIOLASE, Inc. (formerly, Biolase Technology, Inc.) since March 2006 and also served as its Vice President of Asia Pacific Operations. Prior to BIOLASE, he served as the Chief Executive Officer and President of Ellex Medical Pty Ltd. He served as Managing Director and Director of Ellex Medical Lasers Limited until November 4, 2002.
CEO Compensation
- Peter's compensation has increased whilst company is loss making.
- Peter's remuneration is about average for companies of similar size in Australia.
Management Team
Peter Rowland
MD & Executive Director
A$321K
4.6 yrs
Georgina Carpendale
CFO & Company Secretary
A$158K
2.8 yrs
Board of Directors Tenure
Average tenure of the Micro-X board of directors in years:
- The tenure for the Micro-X board of directors is about average.
Board of Directors
Patrick O'Brien
Non Executive Chairman
A$76K
3.7 yrs
Peter Rowland
MD & Executive Director
A$321K
4.6 yrs
Alexander Gosling
Non-Executive Director
A$50K
3.7 yrs
David Peter Symons
Non-Executive Director
A$50K
3.7 yrs
Yasmin King
Non-Executive Director
A$64K
2.3 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (A$) | Value (A$) | |
|---|---|---|---|---|---|---|---|---|---|---|
Management checks
We assess Micro-X's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Micro-X has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
MX1 News
Simply Wall St News
When Will Micro-X Limited (ASX:MX1) Breakeven?
Micro-X Limited designs, develops, and manufactures ultra-lightweight carbon nano tube based X-ray products for the healthcare and improvised explosive device imaging security markets in Australia. … With the latest financial year loss of -AU$16.6m and a trailing-twelve month of -AU$17.9m, the AU$52m market-cap amplifies its loss by moving further away from its breakeven target. … See our latest analysis for Micro-X
Simply Wall St - – Full articleWhat Kind Of Shareholders Own Micro-X Limited (ASX:MX1)?
So it's nice to see some insider ownership, because it may suggest that management is owner-oriented. … With a market capitalization of AU$51m, Micro-X is a small cap stock, so it might not be well known by many institutional investors. … Taking a look at our data on the ownership groups (below), it's seems that.
Simply Wall St - – Full articleIs Micro-X Limited's (ASX:MX1) CEO Being Overpaid?
First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Peter Rowland's Compensation Compare With Similar Sized Companies. … At the time of writing our data says that Micro-X Limited has a market cap of AU$37m, and is paying total annual CEO compensation of AU$321k.
Simply Wall St - – Full articleSuch Is Life: How Micro-X Shareholders Saw Their Shares Drop 51%
Unfortunately, they have held through a 51% decline in the share price in that time. … Given that Micro-X didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. … The share price has moved in quite the opposite direction, down 21% over that time, a bad result.
Simply Wall St - – Full articleAre Micro-X Limited (ASX:MX1) Shareholders Getting A Good Deal?
I’ve analysed below, the health and outlook of Micro-X’s cash flow, which will help you understand the stock from a cash standpoint. … What is free cash flow. … Micro-X’s free cash flow (FCF) is the level of cash flow the business generates from its operational activities, after it reinvests in the company as capital expenditure.
Simply Wall St - – Full articleMicro-X Limited (ASX:MX1): Time For A Financial Health Check
While small-cap stocks, such as Micro-X Limited (ASX:MX1) with its market cap of AU$44.75m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn.
Simply Wall St - – Full articleWant To Invest In Micro-X Limited (ASX:MX1)? Here's How It Performed Lately
After reading Micro-X Limited's (ASX:MX1) most recent earnings announcement (31 December 2017), I found it useful to look back at how the company has performed in the past and compare this against the latest numbers. … How Did MX1's Recent Performance Stack Up Against Its Past. … MX1 is loss-making, with the most recent trailing twelve-month earnings of -AU$10.64m (from 31 December 2017), which compared to last year has become.
Simply Wall St - – Full articleLoss-Making Micro-X Limited (ASX:MX1) Expected To Breakeven
Many investors are wondering the rate at which MX1 will turn a profit, with the big question being “when will the company breakeven?” I’ve put together a brief outline of industry analyst expectations for MX1, its year of breakeven and its implied growth rate. … ASX:MX1 Past Future Earnings May 16th 18 Underlying developments driving MX1’s growth isn’t the focus of this broad overview, though, bear in mind that generally a high forecast growth rate is not unusual for a company that is currently undergoing an investment period. … Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
Simply Wall St - – Full articleAre Micro-X Limited's (ASX:MX1) Interest Costs Too High?
As the purpose of this article is a high-level overview, I won’t be looking at this today, but you can assess some of MX1’s operating efficiency ratios such as ROA here. … MX1’s level of debt is appropriate relative to its total equity, at 28.50%. … Investors' risk associated with debt is very low with MX1, and the company has plenty of headroom and ability to raise debt should it need to in the future.Next Steps: MX1’s cash flow coverage indicates it could improve its operating efficiency in order to meet demand for debt repayments should unforeseen events arise.
Simply Wall St - – Full articleAre Earnings Prospects Improving For Loss-Making Micro-X Limited's (ASX:MX1)?
See our latest analysis for Micro-X Commentary On MX1's Past Performance For the most up-to-date info, I use data from the most recent 12 months, which annualizes the most recent half-year data, or in some cases, the latest annual report is already the most recent financial year data. … For Micro-X, its most recent earnings (trailing twelve month) is -AU$10.64M, which, relative to last year’s level, has become less negative. … This means although Micro-X is currently unprofitable, whatever recent headwind the industry is enduring, Micro-X is relatively better-cushioned than its peers.What does this mean?
Simply Wall St - – Full articleMX1 Company Info
Description
Micro-X Limited designs, develops, and manufactures ultra-lightweight carbon nano tube based X-ray products for the healthcare and improvised explosive device imaging security markets in Australia. The company offers Carestream DRX Revolution Nano, an ultra-lightweight digital mobile X-ray system for use in hospital wards and intensive care units. It is also developing Mobile Backscatter Imager, a small lightweight system for stand-off imaging of improvised explosive devices, as well as Rover for use in military medical facilities. The company was founded in 2011 and is based in Tonsley, Australia.
Details
| Name: | Micro-X Limited |
| MX1 | |
| Exchange: | ASX |
| Founded: | 2011 |
| A$50,080,172 | |
| 151,758,099 | |
| Website: | http://www.micro-x.com |
| Address: |
Micro-X Limited A14, 6 MAB Eastern Promenade, 1284 South Road, Tonsley, South Australia, 5042, Australia |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| ASX | MX1 | Ordinary Shares | Australian Securities Exchange | AU | AUD | 22. Dec 2015 |
Number of employees
Current staff
Industry
| Health Care Equipment | |
| Healthcare |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/04/25 10:35 |
| End of day share price update: | 2019/04/24 00:00 |
| Last estimates confirmation: | 2019/03/18 |
| Last earnings filing: | 2019/02/28 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/06/30 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
